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Aortic Regurgitation with the CoreValve vs. the SAPIEN XT Valve After
Transcatheter Aortic Valve Replacement
Sarkis Kiramijyan, Marco A. Magalhaes, Edward Koifman, Ricardo O. Escarcega,
Nevin C. Baker, Rebecca Torguson, Michael J. Lipinski, Hideaki Ota, Smita I. Negi,
Romain Didier, Thibault Lhermusier, Won Yu Kang, Wenjie Tian, Petros Okubagzi,
William O. Suddath, Itsik Ben-Dor, Lowell F. Satler, Augusto D. Pichard, Ron Waksman
BACKGROUND Aortic regurgitation (AR) after transcatheter aortic valve replacement
(TAVR) has been associated with worse outcomes, and a direct comparison of the
rates of AR between a self-expanding and a balloon-expandable system is not well
established. The study retrospectively examined the rates and severity of AR post
TAVR in an experienced high-volume tertiary center.
METHODS We compared the AR at hospital discharge among patients who underwent
transfemoral TAVR with the CoreValve (CV) vs. the SAPIEN XT Valve (XT). The
baseline, procedural and post-procedural characteristics were compared. The preva-
lence of total AR was assessed by pre-discharge transthoracic echocardiogram and
was categorized in the degree of severity as none or trace, mild, mild-to-moderate,
moderate, moderate-to-severe or severe.
RESULTS Overall, a total 188 patients (54% male, mean 82 years) who had trans-
femoral TAVR with either a CV (n¼101) or an XT (n¼87) were evaluated. There were
no statistically signiﬁcant differences in the rates of any degree of aortic regurgitation
with the CV vs. the XT (Figure). In addition, there was no evidence of more than
moderate aortic regurgitation in either group. Of note, there was a signiﬁcant dif-
ference in the rates of intra-procedural, post-valve implant re-ballooning with the CV
(15%) vs. the XT (5%), p¼0.022.
CONCLUSIONS The prevalence of post-TAVR AR in an experienced high-volume
center is similar between the CV and the XT valve when performed by experienced
operators with optimal post-valve implant re-ballooning, as deemed appropriate.A
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TCharacteristic CV (n[101) XT (n[87) p-ValueRe-ballooning post valve implant 15% (14/94) 5% (4/86) p¼0.022
No or trace pre-DC AR 21% (17/83) 26% (20/78) p¼0.437
Mild pre-DC AR 68% (56/83) 64% (50/78) p¼0.653
Mild-to-moderate pre-DC AR 8% (7/83) 5% (4/78) p¼0.406
Moderate pre-DC AR 4% (3/83) 5% (4/78) p¼0.713
Moderate-to-severe pre-DC AR 0% 0% ————Severe pre-DC AR 0% 0% ————LEFT ATRIAL APPENDAGE
CRT-817
Intentional Right Atrial Exit For Microcatheter Infusion Of Pericardial Carbon
Dioxide Or Iodinated Contrast To Facilitate Sub-xiphoid Access
Toby Rogers, Kanishka Ratnayaka, William Schenke, Anthony Faranesh,
Jonathan Mazal, William O’Neill, Adam Greenbaum, Robert Lederman
NHLBI, National Institutes of Health, Bethesda, MD
BACKGROUND Sub-xiphoid access to the ‘dry’ pericardium is required for structural
and electrophysiological procedures, but is associated with signiﬁcant risk of right
ventricular or coronary artery laceration. If present, an effusion protects the heart
from needle injury by separating the myocardium from the pericardium. We
demonstrate a novel technique to separate visceral and parietal pericardial layers to
facilitate ease and improve safety of sub-xiphoid access.
METHODS The right atrial appendage is catheterized (Fig 1A) and then punctured
using a guidewire, over which a small trans-atrial catheter is advanced into the
pericardium (Fig 1B-C). Contrast (e.g. CO2) is infused to separate pericardial layers
(Fig 1D-E). Sub-xiphoid access is then obtained using standard technique (Fig F-H).
RESULTS Trans-atrial pericardial access was obtained in a total of 30 Yorkshire swine
using 4Fr or 2.8Fr catheters. In 16 animals, trans-atrial catheters were withdrawn
under anticoagulation and MRI was performed to monitor for pericardial hemorrhage.
In 14 animals, iodinated contrast or CO2 was infused before sub-xiphoid access was
obtained. Small effusions (mean 18.5mL) were observed after 4Fr (1.3mm outer-
diameter) but not after 2.8Fr (0.9mm outer-diameter) trans-atrial catheter withdrawal
despite full anticoagulation (mean activated clotting time 383sec), with no hemody-
namic compromise. Pericardial CO2 resorbed spontaneously within 15min and no
coronary compression was observed (Fig I).
CONCLUSION Intentional trans-atrial exit into the pericardium using small catheters
is safe and permits infusion of CO2 or iodinated contrast to separate pericardial layers
and facilitate sub-xiphoid access. 2.8Fr trans-atrial catheter withdrawal does not
cause any pericardial hemorrhage, even under full anticoagulation.CRT-818
Preclinical Study of Novel Generation Watchman FLX Performance for Left Atrial
Appendage (LAA) Occlusion
Dongming Hou, Brian Tischler, Alex Pﬂugfelder, Mindy Jedlicki, Holly Coleman,
Jason Kilvington, Kenneth Stein, Barbara Huibregtse
BSC, Marlborough, MA
BACKGROUND Percutaneous LAA closure is an alternative therapy for prevention of
stroke in high risk patients with nonvalvular AF. Clinical data has demonstrated that
